Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H24N2O2 |
| Molecular Weight | 312.4061 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(C1CCCCC1)N2C[C@@H]3N(CCC4=CC=CC=C34)C(=O)C2
InChI
InChIKey=FSVJFNAIGNNGKK-KRWDZBQOSA-N
InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2/t17-/m0/s1
| Molecular Formula | C19H24N2O2 |
| Molecular Weight | 312.4061 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Praziquantel, (-)- is oxopyrazinoisoquinoline derivative and a levorotated isomer of Praziquantel patented by Merck Patent G.m.b.H. as anthelmintics agent. In rabbits infested with S. japonicum, the therapeutic effect of Praziquantel, (-)-was greater than that of dl-praziquantel as rated by the number of the worms in tissues and by liver damage. Histopathological examination showed that liver egg granulomas in the levo-praziquantel group were fewer in no. and smaller in size and were predominantly composed of Pseudotubercles instead of eosinophilic abscesses. Levo-praziquantel is therapeutically superior to praziquantel, while dextro-praziquantel is almost ineffective.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24982093
mice: 100, 200, or 400 mg/kg
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:00:33 GMT 2025
by
admin
on
Mon Mar 31 22:00:33 GMT 2025
|
| Record UNII |
WF15T5925V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
584317
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
WF15T5925V
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
PRIMARY | |||
|
445900
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
PRIMARY | |||
|
DB11749
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
PRIMARY | |||
|
DTXSID80904739
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
PRIMARY | |||
|
57452-98-9
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
PRIMARY | |||
|
C171715
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
PRIMARY | |||
|
300000010220
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
PRIMARY | |||
|
11106
Created by
admin on Mon Mar 31 22:00:33 GMT 2025 , Edited by admin on Mon Mar 31 22:00:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |